Comparative Pharmacology
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus VIBRA TABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus VIBRA TABS.
OXYTETRACYCLINE HYDROCHLORIDE vs VIBRA-TABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
100 mg orally twice daily on day 1, then 100 mg orally once daily
None Documented
None Documented
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Terminal elimination half-life: 18-22 hours (single dose); increases to 24-48 hours in renal impairment. Mean half-life after multiple doses: 14-16 hours.
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Renal (40% as unchanged drug via glomerular filtration), biliary/fecal (20-30%, including enterohepatic circulation).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic